FABP4 and metabolic dysfunction-associated steatotic liver disease: Since liver steatosis is still a reversible step in the NAFLD progression, serum FABP4 may contribute to identify metabolic patients in the early stages of NAFLD, which would lead to initiate preventive therapies before the disease progression to more advanced irreversible stages, such as NASH or hepatocellular carcinoma.